v3.26.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating Expenses:    
Research and development $ 1,204 $ 2,602
General and administrative 3,738 3,245
Total operating expenses 4,942 5,847
Operating loss (4,942) (5,847)
Other income (expense):    
Investment income, net 120 266
Other expense, net (54) (105)
Total other income 66 161
Net loss before benefit from income taxes and noncontrolling interests (4,876) (5,686)
Benefit from income taxes (387) (962)
Net loss (4,489) (4,724)
Less - net income (loss) attributable to noncontrolling interests 0 0
Net loss attributable to Lisata Therapeutics, Inc. common stockholders $ (4,489) $ (4,724)
Basic and diluted loss per share    
Lisata Therapeutics, Inc. common stockholders- basic (in dollars per share) $ (0.50) $ (0.55)
Lisata Therapeutics, Inc. common stockholders - diluted (in dollars per share) $ (0.50) $ (0.55)
Weighted average common shares outstanding    
Basic shares (in shares) 9,006 8,602
Diluted shares (in shares) 9,006 8,602